特立帕肽对比利塞膦酸对FRAX定义的主要骨质疏松性骨折疗效:VERO临床试验结果
VERO试验纳入1360例严重骨质疏松绝经后女性,随机接受特立帕肽20 μg每日皮下注射或利塞膦酸35 mg每周口服。24个月时,特立帕肽组FRAX定义的主要骨质疏松性骨折风险较利塞膦酸组降低60%(HR 0.40;95%CI 0.23-0.68;p=0.001),骨折风险在治疗7个月时即显著降低。
要点
- 特立帕肽较利塞膦酸降低FRAX定义主要骨质疏松性骨折风险60%。
- 24个月时特立帕肽组发生16例(2.6%),利塞膦酸组40例(6.4%)。
- 两组骨折发生率差异在治疗6-12个月期间最大,7个月即达统计学显著。
核心结论
- 在严重骨质疏松绝经后女性中,特立帕肽比利塞膦酸更有效,24个月治疗期间FRAX定义主要骨质疏松性骨折风险降低60%。
- 骨折风险在治疗7个月时即出现统计学显著降低。
研究设计与样本
- VERO试验为活性药物对照的骨折终点临床试验,纳入1360例严重骨质疏松绝经后女性(平均年龄72.1岁)。
- 患者随机接受皮下每日特立帕肽20 μg或口服每周利塞膦酸35 mg。
- 采用Kaplan-Meier分析估计累积发生率,分层log-rank检验比较组间差异,并用扩展Cox模型估计不同时间点HR。
主要发现
- 24个月时,特立帕肽组16例(2.6%)发生至少1次低创伤FRAX定义主要骨质疏松性骨折,利塞膦酸组40例(6.4%)(HR 0.40;95%CI 0.23-0.68;p=0.001)。
- 临床椎体骨折和桡骨骨折是最常见的FRAX定义主要骨质疏松性骨折部位。
- 两种治疗间FRAX定义主要骨质疏松性骨折和所有临床骨折发生率的最大差异出现在6-12个月期间。
- 对于分析的两种临床骨折类别,组间骨折风险在治疗7个月时即出现统计学显著降低。
关键数值与推荐
- FRAX定义主要骨质疏松性骨折包括临床椎体、髋部、肱骨和前臂骨折。
- 特立帕肽组24个月FRAX定义主要骨质疏松性骨折累积发生率为2.6%,利塞膦酸组为6.4%。
- HR为0.40(95%CI 0.23-0.68;p=0.001)。
临床怎么用
- 对于严重骨质疏松绝经后女性,可考虑特立帕肽以更快速降低FRAX定义主要骨质疏松性骨折风险。
- 治疗7个月时即可观察到骨折风险显著降低,提示早期疗效评估可能有意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: FRAX® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those treated with teriparatide had a 60% lower risk of FRAX®-defined MOF compared with those treated with risedronate. INTRODUCTION: The VERO trial was an active-controlled fracture endpoint clinical trial that enrolled postmenopausal women with severe osteoporosis. After 24 months, a 52% reduction in the hazard ratio (HR) of clinical fractures was reported in patients randomized to teriparatide compared with risedronate. We examined fracture results restricted to FRAX®-defined major osteoporotic fractures (MOF), which include clinical vertebral, hip, humerus, and forearm fractures. METHODS: In total, 1360 postmenopausal women (mean age 72.1 years) were randomized to receive subcutaneous daily teriparatide (20 μg) or oral weekly risedronate (35 mg). Patient cumulative incidence of ≥ 1 FRAX®-defined MOF and of all clinical fractures were estimated by Kaplan-Meier analyses, and the comparison between treatments was based on the stratified log-rank test. Additionally, an extended Cox model was used to estimate HRs at different time points. Incidence fracture rates were estimated at each 6-month interval. RESULTS: After 24 months, 16 (2.6%) patients in the teriparatide group had ≥ 1 low trauma FRAX®-defined MOF compared with 40 patients (6.4%) in the risedronate group (HR 0.40; 95% CI 0.23-0.68; p = 0.001). Clinical vertebral and radius fractures were the most frequent FRAX®-defined MOF sites. The largest difference in incidence rates of both FRAX®-defined MOF and all clinical fractures between treatments occurred during the 6- to 12-month period. There was a statistically significant reduction in fractures between groups as early as 7 months for both categories of clinical fractures analyzed. CONCLUSION: In postmenopausal women with severe osteoporosis, treatment with teriparatide was more efficacious than risedronate, with a 60% lower risk of FRAX®-defined MOF during the 24-month treatment period. Fracture risk was statistically significantly reduced at 7 months of treatment. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT01709110 EudraCT Number: 2012-000123-41.
引用
- Body JJ, Marin F, Kendler DL, et al. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int. 2020. PMID: 32474650. doi:10.1007/s00198-020-05463-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。